Search results

1. J&J claims a Tecvayli/Darzalex combo win

   … J&J’s GPRC5D-targeting T-cell engager Talvey. At ASCO 2024 the company presented results from a safety run-in …

   
    

   Madeleine Armstrong
    
   - 10/16/2025 - 16:33

2. Astra pulls further ahead of Merck’s Curon project

   … being represented in a Chinese phase 1 trial presented at ASCO 2024. Instead, data were reported solely in indolent …

   
    

   Madeleine Armstrong
    
   - 10/16/2025 - 12:33

3. ESMO 2025 preview – Sanofi’s lead shot gets a boost

   … received somatostatin analogue therapy, were presented at ASCO 2024. In a 36 patient-strong radioligand-naive cohort … N 36 26 Venue ASCO 2024 ESMO 2025 Cutoff date 28 May 2024 … meaningful” Source: company release & ASCO 2024.   However, toxicity could be worth …

   
    

   Madeleine Armstrong
    
   - 10/13/2025 - 11:19

4. Chia Tai keeps the TGF-β faith

   … China ph1/2 in solid tumours; initial data at ASCO 2024: 6% ORR HCB301 HanchorBio Fusion …

   
    

   Madeleine Armstrong
    
   - 09/22/2025 - 16:18

5. World Lung 2025 – Candel looks to a new agla-vec use

   … that's relevant since this same study disappointed at ASCO 2024 when a poster revealed an ORR of just 11% among 45 …

   
    

   Jacob Plieth
    
   - 09/12/2025 - 17:50

6. Novocure’s Lunar eclipse

   … NSCLC + supportive care, vs supportive care Data at ASCO 2024: hit primary endpoint, time to intracranial …

   
    

   Madeleine Armstrong
    
   - 09/02/2025 - 15:02

7. Ivonescimab back in tune

   … disclosure highly relevant to the global trial. At ASCO 2024 Harmoni-A showed a highly statistically …   Harmoni-A OS data   Source: ASCO 2024.   Akeso’s latest disclosure, which was …

   
    

   Madeleine Armstrong
    
   - 09/01/2025 - 13:38

8. Arcus reaches the end of the road for etrumadenant

   … a path forward based on the phase 1/2 Arc-9 trial, which at ASCO 2024 showed a 73% reduction in the risk of death with … January 2024 investment reshuffle.   Arc-9 data at ASCO 2024 Source: company presentation. …

   
    

   Madeleine Armstrong
    
   - 08/07/2025 - 18:22

9. 5,000 patients later Roche scraps its TIGIT

   … cards since the molecule put up dismal phase 1 data at ASCO 2024 , so the main surprise will be what took Roche so … RG6614 USP1 inhibitor (ex KSQ) Disappointed in ph1 at ASCO 2024 RO7589831/ RG6457 Werner helicase …

   
    

   Jacob Plieth
    
   - 07/28/2025 - 17:18

10. Sino takes out the rest of Merck’s partner

    … China ph1/2 in solid tumours (monotx & combos); data at ASCO 2024: 13% ORR (2/16) with monotx LM-168 …

    
     

    Madeleine Armstrong
     
    - 07/18/2025 - 13:28